Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.20 +0.40%

+$0.09 today

Market cap
$2.92B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 1.27M

Average 1.84M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$412.60M

FY 2025 · Annual

Investing Cash Flow

$255.28M

FY 2025 · Annual

Financing Cash Flow

$189.22M

FY 2025 · Annual

-60.9% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(290.58M)(325.99M)(145.22M)(422.77M)(512.54M)
Depreciation & Amortization8.59M10.38M16.73M8.99M14.81M
Deferred Income Tax00000
Stock-Based Compensation85.25M99.85M108.1M102.88M99.63M
Change in Working Capital(20.41M)(24.03M)(289.93M)16.94M149K
Accounts Receivables00000
Inventory00000
Accounts Payables3.71M2.27M2.43M1.44M(7.52M)
Other Working Capital(24.12M)(26.3M)(292.36M)15.5M7.67M
Other Non-Cash Items5.76M(4.93M)(47.67M)(53.73M)(14.65M)
Operating Cash Flow(211.39M)(244.72M)(357.99M)(347.69M)(412.6M)
Capital Expenditures(8.5M)(17.83M)(12.94M)(15.91M)(9.5M)
Acquisitions (Net)0123.55M000
Purchases of Investments(1.42B)(1.12B)(1.81B)(1.23B)(441.26M)
Sales of Investments1.41B991.49M2.08B1.16B706.05M
Other Investing Activities0(123.55M)000
Investing Cash Flow(21.63M)(141.39M)249.31M(88.76M)255.28M
Debt Repayment000(32.34M)(8.17M)
Common Stock Issued19.35M296.22M17.82M499.25M197.38M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities014.46M017.39M0
Financing Cash Flow19.35M310.67M17.82M484.3M189.22M
Effect of Forex Changes00(75K)00
Net Change in Cash(213.67M)(75.43M)(90.94M)47.85M31.9M
Free Cash Flow(219.89M)(262.55M)(370.93M)(363.61M)(422.1M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$512.5M
+ D&A$14.8M
+ Stock-Based Comp$99.6M
+ Deferred Tax$0
+ Working Capital$149.0K
- Other Non-Cash-$14.7M
= Operating Cash Flow-$412.6M
- Capex-$9.5M
= Free Cash Flow-$422.1M

Analysis

FY2025 free cash flow is -$422.1M. FCF conversion is 82.4% of net income. Operating cash flow was -$412.6M, with capex of -$9.5M. The largest bridge item is Stock-Based Comp at $99.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
8-KCurrent reportNov 3, 2026
10-QQuarterly reportNov 3, 2026
4Statement of changes in beneficial ownershipSep 9, 2026
4Statement of changes in beneficial ownershipSep 4, 2026
4Statement of changes in beneficial ownershipSep 3, 2026

Does DNLI generate free cash flow?

Denali Therapeutics Inc. (DNLI) generated -$422.10M of free cash flow in fiscal 2025.

How much operating cash flow does DNLI produce?

Operating cash flow was -$412.60M, before capital expenditures of $9.50M.